Market Research Report
Outsourcing in Drug Development: The Contract CRO, Clinical Trial Lab and EDC Market
|Published by||Kalorama Information||Product code||225424|
|Published||Content info||235 Pages
|Outsourcing in Drug Development: The Contract CRO, Clinical Trial Lab and EDC Market|
|Published: January 1, 2012||Content info: 235 Pages||
This publication has been discontinued on May 3, 2016.
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years.
Contract Research Organizations (CROs) and other entities can expect growing demand for their services. The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
As part of its comprehensive coverage of this market, this report contains:
As part of Kalorama Information's research process, information for this report is gathered from sources including trade press, company reports and government databases. Kalorama Information's analyst also interviewed dozens of experts in the industry to discover new trends and confirm assumptions.
As part of the report's coverage , the following CROs, clinical trial laboratories, EDC companies and site management networks are profiled:
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
Drug development has become increasingly global as sponsors seek to accelerate patient recruitment by gaining access large treatment-naive patient populations, broaden access to trained investigators, and reduce clinical trial costs. Today clinical research is being conducted in Eastern Europe, Asia and Latin America, as well as other geographic regions. However, the United States remains the world's largest clinical research market.
ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. The clinicaltrials.gov information resource was initiated as a result of the Food and Drug Administration Modernization Act of November 1997. The legislation requires the Department of Health and Human Services, through the NIH, to establish a registry of clinical trials for both federally and privately funded trials of experimental treatments for serious or life-threatening diseases or conditions